Yigal Nochomovitz

Work

Analyst Yigal Nochomovitz works at CITI and is focused on the Healthcare sector with 580 price targets and ratings documented since 2015 spanning on 41 stocks. Analyst's average stock valuation to be materialised ratio is 49.45% with an average time for price targets to be met of 148.66 days.

Most recent stock forecast was given on ARVN, Arvinas, Inc at 05-Dec-2022.

Yigal Nochomovitz best performing recommendations are on UBX (UNITY BIOTECHNOLOGY, INC).
The best stock recommendation documented was for LXRX (LEXICON PHARMACEUTICALS, INC) at 1/13/2021. The price target of $6 was fulfilled within 1 day with a profit of $2.08 (53.06%) receiving and performance score of 530.61.

Average potential price target upside

AERI ALDX APLS ARCT ARDX ARVN ATRA CLLS CRBU CRSP DRNA EIGR FATE HARP IMRA IPHA LXRX MGNX MRTX MRUS ORIC OVID PBYI PRQR PTLA RARE RETA RIGL UBX XLRN ZLAB ZYME APLT CALT GRTX RCUS CMRX OPT SNDX SYBX RAIN
AERI ALDX APLS ARCT ARDX ARVN ATRA CLLS CRBU CRSP DRNA EIGR FATE HARP IMRA IPHA LXRX MGNX MRTX MRUS ORIC OVID PBYI PRQR PTLA RARE RETA RIGL UBX XLRN ZLAB ZYME APLT CALT GRTX RCUS CMRX OPT SNDX SYBX RAIN